Common Wart disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Disease Ontology: ¹¹ A viral infectious disease that results in infection located in skin, has material basis in human papillomavirus (types 2 and 4). This infection is characterized by a raised wart with roughened surface, most common on hands, but can grow anywhere on the body.

MalaCards based summary: Common Wart, also known as verruca vulgaris, is related to plantar wart and keratosis, seborrheic. An important gene associated with Common Wart is MIR1914 (MicroRNA 1914), and among its related pathways/superpathways is BARD1 signaling events. The drugs Cantharidin and Copper have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and nk cells.

Sources

Related Diseases for Common Wart

Diseases related to Common Wart via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 174)

#	Related Disease	Score	Top Affiliating Genes
1	plantar wart	30.6	TMC8 TMC6
2	keratosis, seborrheic	30.3	TP53 TMC8 TMC6
3	acanthoma	30.2	TP53 TMC8 TMC6
4	focal epithelial hyperplasia	30.0	TP53 TMC8 TMC6
5	superficial basal cell carcinoma	29.7	TLR7 IFNA1 CD4
6	anogenital venereal wart	29.5	TP53 TMC8 TLR7 IFNA1 CD4
7	chickenpox	29.5	IFNA1 DOCK8 CD4
8	skin carcinoma	29.3	TP53 TMC8 TMC6 TLR7 CD4
9	epidermodysplasia verruciformis 1	29.2	TP53 TMC8 TMC6 DOCK8 CD4 CCDC39
10	clear cell acanthoma	11.2
11	papilloma	10.6
12	viral infectious disease	10.4
13	keratosis	10.4
14	basal cell carcinoma 1	10.3
15	basal cell carcinoma	10.3
16	angiokeratoma of fordyce	10.3	TMC8 TMC6
17	pityriasis versicolor	10.2	TMC8 TMC6
18	molluscum contagiosum	10.2
19	dendritic cell thymoma	10.2	PCNA CD4
20	dilution, pigmentary	10.1
21	vitiligo-associated multiple autoimmune disease susceptibility 6	10.1
22	leprosy 3	10.1
23	vitiligo-associated multiple autoimmune disease susceptibility 1	10.1
24	lepromatous leprosy	10.1
25	squamous cell carcinoma	10.1
26	dermatitis	10.1
27	keratoacanthoma	10.1
28	skin squamous cell carcinoma	10.1
29	epidermolytic acanthoma	10.1
30	syringocystadenoma papilliferum	10.1
31	inverted follicular keratosis	10.1
32	superficial mycosis	10.1	TMC8 TMC6 CD4
33	suppurative lymphadenitis	10.1	DOCK8 CD4
34	blepharoconjunctivitis	10.1	DOCK8 CD4
35	fibrillary astrocytoma	10.1	TP53 PCNA
36	mastoiditis	10.1	DOCK8 CD4
37	whim syndrome 1	10.1	TMC8 TMC6 DOCK8
38	external ear disease	10.1	DOCK8 CD4
39	lung abscess	10.1	DOCK8 CD4
40	subcutaneous mycosis	10.0	TLR7 CD4
41	otitis externa	10.0	DOCK8 CD4
42	skin tag	10.0
43	immune-complex glomerulonephritis	10.0	TLR7 CD4
44	immunodeficiency 14	10.0	DOCK8 CD4
45	anal squamous cell carcinoma	10.0	TP53 CD4
46	immunodeficiency 41 with lymphoproliferation and autoimmunity	10.0	DOCK8 CD4
47	acanthosis nigricans	10.0
48	epidermolytic hyperkeratosis	10.0
49	darier-white disease	10.0
50	lentigines	10.0

Graphical network of the top 20 diseases related to Common Wart:

Sources

Symptoms & Phenotypes for Common Wart

Sources

Drugs & Therapeutics for Common Wart

Drugs for Common Wart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Cantharidin

Approved, Investigational

Phase 4

56-25-7

2545

2

Copper

Approved, Investigational

Phase 4

7440-50-8

27099

3

Vaccines

Phase 4

4

Copper Supplement

Phase 4

5

Ethanol

Approved

Phase 3

64-17-5

702

6

Hydrogen peroxide

Approved, Vet_approved

Phase 3

7722-84-1

784

7

Povidone-iodine

Approved

Phase 2

25655-41-8

8

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

9

Povidone K30

Approved, Experimental, Withdrawn

Phase 2

9003-39-8

6917 131751496

10

Cadexomer iodine

Experimental

Phase 2

94820-09-4

11

Anti-Infective Agents

Phase 2

12

Anti-Infective Agents, Local

Phase 2

13

Blood Substitutes

Phase 2

14

Plasma Substitutes

Phase 2

15

Aminolevulinic acid

Approved

106-60-5

137

16

Methylene blue

Approved, Investigational

61-73-4

6099

17

Cholecalciferol

Approved, Nutraceutical, Vet_approved

67-97-0, 1406-16-2

5280795 10883523

18

Vitamins

19

Trace Elements

20

Calciferol

21

Hormones

22

Calcium, Dietary

23

Micronutrients

24

Pharmaceutical Solutions

25

Immunologic Factors

26

Immunoglobulins, Intravenous

27

Immunoglobulins

28

Antibodies, Monoclonal

29

Antibodies

30

Calcium

Nutraceutical

7440-70-2

271

Interventional clinical trials:

(show all 26)

#	Name	Status	NCT ID	Phase	Drugs
1	Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial	Completed	NCT03183765	Phase 4	Measles-Mumps-Rubella Vaccine
2	Study to Evaluate the Efficacy of 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts.	Recruiting	NCT03977753	Phase 4	2LVERU® or 2LVERU® JUNIOR;Placebo
3	Using a Cold Atmospheric Plasma Device to Treat Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients	Recruiting	NCT05070754	Phase 4	Canthardin Collodion
4	Efficacy of Cryotherapy Combined With Intralesional Tuberculin Purified Protein Derivative (PPD) Versus Interlesional Tuberculin PPD Monotherapy in the Treatment of Multiple Common Warts	Unknown status	NCT04288817	Phase 3
5	A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts	Completed	NCT03691831	Phase 3	Active
6	A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts	Completed	NCT03687372	Phase 3	A-101
7	A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts	Completed	NCT03812510	Phase 3	A-101
8	A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years	Unknown status	NCT02640820	Phase 2	Sensitizing DPCP Ointment;Treatment DPCP Ointment
9	A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts	Completed	NCT03278028	Phase 2	A-101 Topical Solution;A-101 Vehicle Solution
10	A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Once a Week in Subjects With Common Warts	Completed	NCT03210337	Phase 2	A-101 Topical Solution;A-101 Vehicle Solution
11	A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)	Completed	NCT03487549	Phase 2
12	A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)	Completed	NCT02393417	Phase 2
13	ALC-919 For The Treatment Of Common Warts (Verruca Vulgaris)	Completed	NCT02483455	Phase 2	2014-ALC-919-US;Vehicle-Control Topical Solution
14	A Randomized, Double-blind, Multi-center, Placebo-controlled, Dose-ranging, Efficacy and Safety Trial of a New Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts (Verruca Vulgaris)	Completed	NCT01286441	Phase 2	10% EISO;Placebo;20% EISO;30% EISO
15	A Phase 2, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Study to Evaluate Topical 2% Povidone-Iodine Gel (VBP-245) in Subjects With Verruca Vulgaris	Active, not recruiting	NCT04253912	Phase 2	VBP-245;Placebo Gel (no Povidone-Iodine)
16	A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.	Suspended	NCT01796795	Phase 2	Vehicle gel;SR-T100 gel with 1.0% of SM;SR-T100 gel with 2.3% of SM
17	An Open Label Exploratory Study Evaluating the Efficacy and Safety of Ingenol Mebutate 0.05% Gel for the Treatment of Verruca Vulgaris.	Completed	NCT02748902	Phase 1	ingenol mebutate 0.05% gel
18	A Phase I, Single-Centre, Open-Label, Fixed-Dose Study of the Safety and Efficacy of up- to Three-Days Application of 0.05% PEP005 Topical Gel in the Treatment of Patients With Common Wart(s) (Verruca[e] Vulgaris) on the Dorsal Hand	Withdrawn	NCT00546611	Phase 1	PEP005
19	Topical 5-Aminolevulinic Acid Photodynamic Therapy for the Treatment of Verruca Vulgaris: Comparison of Red and Green Light-Emitting Diode Array	Unknown status	NCT00155584
20	Double-Blind, Randomized Control Trial To Evaluate the Efficacy of Duct Tape Versus Placebo for the Treatment of Verruca Vulgaris	Completed	NCT00328991
21	A Randomized Clinical Trial Examining the Efficacy of Treatment of Cutaneous Verruca Vulgaris in Adult Patients With Combined Liquid Nitrogen Cryotherapy and Topically Applied Cantharidin	Completed	NCT01084824		Liquid nitrogen and cantharidin;Liquid nitrogen and topical placebo
22	Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study	Completed	NCT04793529		Cholecalciferol
23	Prospective, Open Clinical Investigation to Evaluate the Effectiveness and Safety of Wortie® Freeze Plus in the Treatment of Common Warts and Plantar Warts	Recruiting	NCT05115669
24	Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris	Recruiting	NCT05409365
25	PHOTODYNAMIC THERAPY USING METHYLENE BLUE AND INTENSE PULSED LIGHT VERSUS INTENSE PULSED LIGHT ALONE IN TREATMENT OF VERRUCA :A RANDOMIZED CONTROLLED STUDY	Recruiting	NCT04620785
26	Randomized Double Blind Study Comparing Liquid Nitrogen Cryotherapy With Nd:YAG in the Treatment of Verruca Vulgaris	Terminated	NCT01609530

Search NIH Clinical Center for Common Wart

Sources

Genetic Tests for Common Wart

Sources

Anatomical Context for Common Wart

Organs/tissues related to Common Wart:

FMA: Skin

MalaCards : Skin, Tongue, Nk Cells, Bone Marrow, Bone, Kidney, Breast

Sources

Publications for Common Wart

Articles related to Common Wart:

(show top 50) (show all 554)

#	Title	Authors	PMID	Year
1	Expression of cell-cycle proteins p53, p21 (WAF-1), PCNA and Ki-67 in benign, premalignant and malignant skin lesions with implicated HPV involvement. ⁵³ ⁶²	Lu S...Syrjanen S	10429981	1999
2	PCNA expression in cutaneous keratinous neoplasms and verruca vulgaris. ⁵³ ⁶²	Penneys NS...Sisto M	1352943	1992
3	Prevalence of skin diseases and prognosis of atopic dermatitis in primary school children in populated areas of Japan from 2010 to 2019: The Asa Study in Hiroshima, Japan. ⁶²	Tanaka A...Okano S	36120740	2022
4	Characterizing Skin Cancer in Transplant Recipients by Fitzpatrick Skin Phototype. ⁶²	Shope CN...Lee LW	36469283	2022
5	Epidemiologic Differences and Management of Eyelid Lesions in the Pediatric Population. ⁶²	Sheng J...Allen RC	35275778	2022
6	Efficacy and safety of date palm leaf-based ointment for treatment of cutaneous warts: A pilot clinical trial. ⁶²	Ayatollahi A...Saber M	36346021	2022
7	The efficacy and safety of intralesional Candida vaccine versus topical diphencyproprobenone in immunotherapy of verruca vulgaris: A randomized comparative study. ⁶²	El-Komy MHM...Bedair NI	36245011	2022
8	An Improved Protocol for Comprehensive Etiological Characterization of Skin Warts and Determining Causative Human Papillomavirus Types in 128 Histologically Confirmed Common Warts. ⁶²	Skubic L...Poljak M	36298821	2022
9	Recalcitrant verruca vulgaris regression following severe SARS-CoV-2 infection. ⁶²	Barzallo D...Leslie KS	35966354	2022
10	[Nail disorders in daily practice]. ⁶²	Hetterschijt CRM...Pasch MC	36300431	2022
11	Annular rupioid secondary syphilis confined to the face. ⁶²	Yu T...Yang J	35842215	2022
12	Falkner's needling technique for the treatment of warts: Minimum investment, maximum benefit. ⁶²	Baveja S...Venugopal R	36147396	2022
13	Changing Trends in Benign Human Papillomavirus (HPV) Related Epithelial Neoplasms of the Oral Cavity: 1995-2015. ⁶²	Alramadhan SA...Cohen DM	35257322	2022
14	HPV-57 Verruca Vulgaris Mimicking Epidermodysplasia Verruciformis. ⁶²	Kirchner A...Mehta S	35642965	2022
15	Vaccination against human papillomavirus is not associated with resolution of verruca vulgaris in immunocompetent 9- to 21-year olds. ⁶²	Kost Y...Blasiak RC	34418514	2022
16	Our experience using 1064 nm Nd:YAG in palmoplantar warts. ⁶²	Le HTT...Al-Niaimi F	35833729	2022
17	Successful treatment of tuberculosis verrucosa cutis with fester as primary manifestation with photodynamic therapy and anti-tubercular drugs. ⁶²	Zhang Z...Cao X	35189390	2022
18	Clinical efficacy evaluation of 595-nm pulsed dye lasers, microwave tissue coagulation, and liquid nitrogen cryotherapy in the treatment of verruca vulgaris in children. ⁶²	Zhuang B...Guo Y	35357763	2022
19	Psychosocial Burden of Verruca Vulgaris: A Cross-Sectional Survey. ⁶²	Adusumilli N...Friedman A	35674752	2022
20	Verruca Vulgaris Eruption Arising in the Setting of a Tyrosine Kinase Inhibitor. ⁶²	Muskat A...McLellan B	35855241	2022
21	Spontaneous resolution of Verruca Vulgaris in a paediatric atopic dermatitis patient treated with dupilumab. ⁶²	Shen CP...Ma L	35044007	2022
22	Breast horn; A rare case presentation. ⁶²	Varughese B...Nik Lah NAS	35638062	2022
23	Comparison of Effectiveness and Safety of Immunotherapy of Warts with Intralesional Versus Subcutaneous MMR Vaccine: An Open Label Randomized, Parallel Group, Clinical Trial. ⁶²	Saha A...Bandyopadhyay D	36092192	2022
24	Dermoscopy of inflamed seborrheic keratosis: A great mimic of malignancy. ⁶²	Alvarez-Salafranca M...Zaballos P	34958128	2022
25	Intralesional Bleomycin Combined With Cryotherapy in the Treatment of Recalcitrant Verruca Vulgaris. ⁶²	Mesgarzadeh S...Curiel-Lewandrowski C	35133103	2022
26	Rare Report Case of Oral Verruca Vulgaris on Torus Palatinus. ⁶²	Khoo LK...Wongsirichat N	34674196	2022
27	Intralesional injection of vitamin D in verruca vulgaris increases cathelicidin (LL37) expression; therapeutic and immunohistochemical study. ⁶²	Sorour NE...Akl EM	32237947	2022
28	Clinical presentation of verruca vulgaris in HIV. ⁶²	Leavens J...Ahronowitz I	35499409	2022
29	Expression Patterns of Macrophage Migration Inhibitory Factor and Its Gene Variants (MIF-173 G˃C) in Verruca Vulgaris. ⁶²	Hassan MH...Abd-Elmagid WM	35712358	2022
30	Impacts of COVID-19 Pandemic on Dermatology Outpatient Department at a Tertiary Hospital in Eastern China: A Pre-Post Study. ⁶²	Yan T...Chai D	36426104	2022
31	Only plantar lesion of punctate palmoplantar keratoderma with a novel missense mutation in the AAGAB gene: Two Japanese familial case reports and review of reported mutations. ⁶²	Hasegawa A...Abe R	34535911	2021
32	Cutaneous Horn Revisited: A Woman With a Verruca Vulgaris-Associated Cornu Cutaneum. ⁶²	Kheshvadjian AR...Cohen PR	34976525	2021
33	Topical cidofovir for benign human papillomavirus-associated skin lesions. ⁶²	Napolitano L...Shea CR	35485335	2021
34	Role of Intralesional Vitamin D3 in the Treatment of Cutaneous Warts. ⁶²	Latif I...Devi R	35283599	2021
35	Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial. ⁶²	Nomura T...Kabashima K	34909725	2021
36	Does involucrin have a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study. ⁶²	Akl EM...Elesawy FM	35068499	2021
37	Verruca Vulgaris Arising Within the Red Portion of a Multicolored Tattoo. ⁶²	Sahni D...Mochel MC	34735332	2021
38	Remission of verruca vulgaris following incisional punch biopsy. ⁶²	Ralph J...Barry R	33734465	2021
39	Verruca Vulgaris Occurring on a Tattoo: Case Report and Review of Tattoo-Associated Human Papillomavirus Infections. ⁶²	Cohen PR	34646630	2021
40	Cd34+ Stromal Cells/Telocytes in Normal and Pathological Skin. ⁶²	Diaz-Flores L...Carrasco JL	34298962	2021
41	COVID-19 and human papillomavirus: Paradoxical immunity. ⁶²	Demirbas A...Lotti T	33626241	2021
42	Intraoral Verruca Vulgaris. ⁶²	Sen S...Sen S	34137563	2021
43	Efficacy of tuberculin immunotherapy in verruca vulgaris: Our experience from single center from North-West India and review of literature. ⁶²	Gogia P...Garg G	33528095	2021
44	Combination of squamous cell carcinoma and basal cell carcinoma arising from a giant verruca vulgaris involving the eyelid. ⁶²	Lai KKH...Ko SC	33553803	2021
45	A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections. ⁶²	McEwan T...Robinson PC	33360321	2021
46	Epithelioid Sarcoma in a Young Child: A Case Report and Literature Review. ⁶²	Talbet JH...Rogers GF	33680643	2021
47	Tattoo-Associated Viral Infections: A Review. ⁶²	Cohen PR	34720594	2021
48	Expression and Significance of AQP3 in Cutaneous Lesions. ⁶²	Niu D...Zhao C	34745849	2021
49	[Fire needling stripping after local anesthesia for verruca vulgaris: a multi-center randomized controlled trial]. ⁶²	Xu JT...Fang YF	33559445	2021
50	Verruciform Xanthoma of the Ventral Surface of the Tongue: A Rare Case Report and Literature Review. ⁶²	Atarbashi-Moghadam S...Sijanivandi S	33654692	2021

Sources

Genes for Common Wart

Genes related to Common Wart (0 elite genes):

(show all 16)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MIR1914	MicroRNA 1914	RNA Gene	6.67	DISEASES inferred ¹⁴ ¹⁴
2	TMC8	Transmembrane Channel Like 8	Protein Coding	6.61	DISEASES inferred ¹⁴
3	TMC6	Transmembrane Channel Like 6	Protein Coding	5.96	DISEASES inferred ¹⁴
4	INSYN1	Inhibitory Synaptic Factor 1	Protein Coding	5.62	DISEASES inferred ¹⁴
5	CYB561A3	Cytochrome B561 Family Member A3	Protein Coding	5.17	DISEASES inferred ¹⁴
6	C12orf71	Chromosome 12 Open Reading Frame 71	Protein Coding	5.15	DISEASES inferred ¹⁴
7	PCNA	Proliferating Cell Nuclear Antigen	Protein Coding	5.1	Novoseek inferred ⁵³	1352943 10429981
8	UNC5B-AS1	UNC5B Antisense RNA 1	RNA Gene	5.1	DISEASES inferred ¹⁴
9	SH3PXD2A-AS1	SH3PXD2A Antisense RNA 1	RNA Gene	5.09	DISEASES inferred ¹⁴
10	FER1L6-AS1	FER1L6 Antisense RNA 1	RNA Gene	4.96	DISEASES inferred ¹⁴
11	CD4	CD4 Molecule	Protein Coding	4.9	DISEASES inferred ¹⁴
12	CCDC39	Coiled-Coil Domain Containing 39	Protein Coding	4.66	DISEASES inferred ¹⁴
13	DOCK8	Dedicator Of Cytokinesis 8	Protein Coding	4.62	DISEASES inferred ¹⁴
14	TP53	Tumor Protein P53	Protein Coding	4.62	DISEASES inferred ¹⁴
15	IFNA1	Interferon Alpha 1	Protein Coding	4.61	DISEASES inferred ¹⁴
16	TLR7	Toll Like Receptor 7	Protein Coding	4.6	DISEASES inferred ¹⁴

Sources

Variations for Common Wart

Sources

Expression for Common Wart

Search GEO for disease gene expression data for Common Wart.

Sources

Pathways for Common Wart

Pathways related to Common Wart according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	BARD1 signaling events ⁶¹	10.09	TP53 PCNA

Sources

GO Terms for Common Wart

Molecular functions related to Common Wart according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mechanosensitive monoatomic ion channel activity	GO:0008381	8.92	TMC8 TMC6

Sources

Sources for Common Wart

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

MCID: CMM003 MIFTS: 34	Common Wart Categories: Infectious diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables